All In MedTech

FDA Clearance Tracker · P230013-S016

Edwards EVOQUE Transcatheter Tricuspid Valve Replacement System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 13, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 13, 2025

Approved

Time to decision

57 days

Received Jun 17, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P230013-S016
Device name
Edwards EVOQUE Transcatheter Tricuspid Valve Replacement System
Applicant location
Irvine, CA
Received
Jun 17, 2025
Decided
Aug 13, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P230013

Device type

Device class
Class III

Every decision under product code NPW

FDA's approval statement

As written in FDA's record.

approval to add the Edwards Singapore facility, located in Changi, Singapore, as a qualified manufacturing site for the EVOQUE valve component of the EVOQUE TTVR System

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.